D-Index & Metrics Best Publications

Donald Milligan

University of Birmingham
United Kingdom

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 73 Citations 19,770 246 World Ranking 15718 National Ranking 1428

Overview

What is he best known for?

The fields of study Donald Milligan is best known for:

Chemotherapy
Hematopoietic stem cell transplantation
Leukemia

Borrowing concepts from Gastroenterology, Donald Milligan weaves in ideas under Oncology. By researching both Gastroenterology and Oncology, he produces research that crosses academic boundaries. The study of Internal medicine is intertwined with the study of Randomized controlled trial in a number of ways. Many of his studies involve connections with topics such as Internal medicine and Randomized controlled trial. He connects Leukemia with Minimal residual disease in his research. Donald Milligan combines topics linked to Genetics with his work on Minimal residual disease. His study brings together the fields of Stem cell and Genetics. Donald Milligan incorporates Stem cell and Hematopoietic stem cell transplantation in his research. Chronic lymphocytic leukemia is closely attributed to Immunology in his study.

His most cited work include:

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial (948 citations)
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus (369 citations)
Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen (230 citations)

What are the main themes of his work throughout his whole career to date

His Internal medicine study frequently draws parallels with other fields, such as Confidence interval. His Internal medicine research extends to the thematically linked field of Confidence interval. Surgery is often connected to Cyclophosphamide in his work. His research combines Surgery and Cyclophosphamide. He merges many fields, such as Chemotherapy and Etoposide, in his writings. Donald Milligan integrates several fields in his works, including Etoposide and Chemotherapy. By researching both Gastroenterology and Oncology, he produces research that crosses academic boundaries. He connects Oncology with Gastroenterology in his study. His research is interdisciplinary, bridging the disciplines of Cumulative incidence and Transplantation.

Donald Milligan most often published in these fields:

Internal medicine (64.10%)
Surgery (43.59%)
Chemotherapy (41.03%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

D C Linch;D Winfield;A H Goldstone;D Moir.
The Lancet (1993)

1330 Citations

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

D Catovsky;S Richards;E Matutes;D Oscier.
The Lancet (2007)

893 Citations

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study

Peter J Campbell;Linda M Scott;Georgina Buck;Keith Wheatley.
The Lancet (2005)

851 Citations

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment†‡

Alan Kenneth Burnett;Donald Milligan;Archie G. Prentice;Anthony H. Goldstone.
Cancer (2007)

764 Citations

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

Alan Kenneth Burnett;Robert Kerrin Hills;Donald Milligan;Lars Kjeldsen.
Journal of Clinical Oncology (2011)

674 Citations

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.

Panagiotis D Kottaridis;Donald W Milligan;Rajesh Chopra;Ronjon Chakraverty.
Blood (2000)

601 Citations

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

P Dreger;P Corradini;E Kimby;M Michallet.
Leukemia (2007)

463 Citations

Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery

Suparno Chakrabarti;Vivien Mautner;Vivien Mautner;Husam Osman;Husam Osman;Kathryn E Collingham;Kathryn E Collingham.
Blood (2002)

462 Citations

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.

Suparno Chakrabarti;Stephen Mackinnon;Rajesh Chopra;Panagiotis D Kottaridis.
Blood (2002)

427 Citations

Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia

Alan Kenneth Burnett;Nigel H. Russell;Robert Kerrin Hills;Jonathan Kell.
Journal of Clinical Oncology (2012)

406 Citations

If you think any of the details on this page are incorrect, let us know.